Bruker 8-K

PositiveEarningsGuidance reaffirmedImpairment / charge

BSI bookings strengthened as organic revenue growth resumed; a noncash goodwill impairment contributed to a GAAP operating loss.

Filed 2026-08-04 07:00 ET

Summary

Q2 2026 results and updated FY2026 guidance. Revenue returned to organic growth, while a $134.9M noncash goodwill impairment contributed to a GAAP operating loss. Bruker updated its outlook for currency and tax only; management also cited a gradual market recovery and expects significant organic margin expansion and non-GAAP EPS growth in 2027.

Key Figures

Metric Q2 2026 Q2 2025 Y/Y
Revenue $838.5M $797.4M 5.2%
GAAP operating income (loss) $(65.3)M $11.9M n/m
Non-GAAP operating income $118.5M $72.0M 64.6%
GAAP net income (loss) attributable to Bruker Corporation common shareholders $(62.9)M $7.6M n/m
Non-GAAP net income attributable to Bruker Corporation common shareholders $75.6M $48.3M 56.5%
GAAP diluted EPS $(0.41) $0.05 n/m
Non-GAAP diluted EPS $0.49 $0.32 53.1%
Net cash used in operating activities $(77.4)M $(127.5)M n/m
Non-GAAP free cash flow $(106.2)M $(148.8)M n/m
  • Q2 organic revenue increased 2.8% (3.4% excluding tariff refunds); BSI organic bookings rose 10% and book-to-bill was >1.0x. Non-GAAP operating margin expanded to 14.1% from 9.0%; the GAAP results included the $134.9M impairment charge.
  • H1 revenue was $1.66B, up 3.9% Y/Y, while organic revenue declined 0.8%. GAAP operating loss was $(55.1)M vs operating income of $43.7M; diluted GAAP EPS was $(0.39) vs $0.16, while non-GAAP diluted EPS was $0.80 vs $0.78.
  • H1 net cash used in operating activities was $(6.2)M vs $(62.5)M; non-GAAP free cash flow was $(59.2)M vs $(109.8)M. At 6/30/2026, cash and cash equivalents were $184.9M and long-term debt carrying value was $1.81B.

Guidance

Metric Period Guidance Prior Direction
Revenue (reported) FY2026 $3.54B-$3.57B; 3%-4% Y/Y — —
Organic revenue growth (non-GAAP) FY2026 1%-2% — —
M&A revenue growth (non-GAAP) FY2026 ≈1.5% — —
CER revenue growth (non-GAAP) FY2026 2.5%-3.5% — —
Foreign currency translation revenue impact FY2026 ≈0.5% tailwind 1.5% tailwind Lowered
Non-GAAP diluted EPS FY2026 $2.10-$2.15; 15%-17% Y/Y — Reaffirmed
Effective non-GAAP tax rate FY2026 27.5% — —

Investor Takeaways

  • Watch whether BSI’s bookings growth converts into sustained organic revenue growth, especially while U.S. academic demand remains soft.
  • Bruker’s stated 2027 outlook calls for significant organic margin expansion and non-GAAP EPS growth; subsequent results will show whether that trajectory is developing.

The summary is written by an AI model reading the filing.

Model 005 · prompt 01d34d48e3

Feedback